The procholinergic effects of the atypical antipsychotic olanzapine are independent of muscarinic autoreceptor inhibition [4]

Molecular Psychiatry

Volumn 11, Issue 7, 2006, Pages 619-621

  Tzavara, E T ^a,b   Bymaster, F P ^a   Nomikos, G G ^a  

^a ELI LILLY AND COMPANY   (United States)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC RECEPTOR; OLANZAPINE; SCOPOLAMINE;

ACETYLCHOLINE RELEASE; ANIMAL EXPERIMENT; CONTROLLED STUDY; HIPPOCAMPUS; LETTER; MICRODIALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ACETYLCHOLINE; ANIMALS; ANTIPSYCHOTIC AGENTS; AUTORECEPTORS; BENZODIAZEPINES; CHOLINERGIC AGENTS; CLOZAPINE; COGNITION; HIPPOCAMPUS; HUMANS; MEMORY; MICE; MICE, KNOCKOUT; MICRODIALYSIS; MUSCARINIC ANTAGONISTS; RECEPTOR, MUSCARINIC M2; RECEPTOR, MUSCARINIC M3; RECEPTOR, MUSCARINIC M4; SCOPOLAMINE;

EID: 33745616494     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/sj.mp.4001834     Document Type: Letter

References (10)

1. Everitt BJ, Robbins TW. Central cholinergic systems and cognition. Annu Rev Psychol 1997; 48: 649-684.
2. Tzavara ET, Bymaster FP, Overshiner CD, Davis RJ, Perry KW, Wolff M et al. Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine. Mol Psychiatry 2006; 11: 187-195.
3. Ichikawa J, Dai J, O'Laughlin IA, Fowler WL, Meltzer HY. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 2002; 26: 325-339.
4. Shirazi-Southall S, Rodriguez DE, Nomikos GG. Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology 2002; 26: 583-594.
5. Johnson DE, Nedza FM, Spracklin DK, Ward KM, Schmidt AW, Iredale PA et al. The role of muscarinic receptor antagonism in antipsychotic-induced hippocampal acetylcholine release. Eur J Pharmacol. 2005; 506: 209-219.
6. Raedler TJ, Knable MB, Jones DW, Lafargue T, Urbina RA, Egan MF et al. In vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia. Neuropsychopharmacology 2000; 23: 56-68.
7. Tzavara ET, Bymaster FP, Felder CC, Wade M, Gomeza J, Wess J et al. Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice. Mol Psychiatry 2003; 8: 673-679.
8. Seeger T, Fedorova I, Zheng F, Miyakawa T, Koustova E, Gomeza J et al. M2 muscarinic acetylcholine receptor knockout mice show deficits in behavioral flexibility, working memory, and hippocampal plasticity. J Neurosci 2004; 24: 10117-10127.
9. Tzavara ET, Bymaster FP, Davis RJ, Wade MR, Perry KW, Wess J et al. M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies. FASEB J 2004; 18: 1410-1412.
10. Yamada M, Miyakawa T, Duttaroy A, Yamanaka A, Moriguchi T, Makita R et al. Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean. Nature (London) 2001; 410: 207-212.